Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 24 Issue 12, December 2023

Cancer immunology and immunotherapy

Nature Immunology has commissioned a series of Reviews to make sense of interactions between immune cells and cancer cells, highlighting the value of spatial and other omic technologies for analysis of the tumor microenvironment, immune cell dysfunction and how to counter it to enhance CAR-based and other immunotherapies, and more.

See:

Image credit: Haiming Wei, University of Science and Technology of China. Cover design: Amie Fernandez

Editorial

Top of page ⤴

Obituary

Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

  • The immune response to dengue virus infection is a well-coordinated balancing act. New research shows that an imbalanced response — driven partially by the productive infection of antigen-presenting cells — is associated with progression to severe disease.

    • Camila D. Odio
    • Rosemary A. Aogo
    • Leah C. Katzelnick
    News & Views
  • Regulatory T (Treg) cells maintain the balance between immune protection and pathology. Research has now found that intestinal Treg cells produce IL-27 to restrain TH17 cell-mediated immune responses, effectively restricting autoimmune inflammation and limiting T cell responses to certain gut pathogens.

    • Emily R. Siniscalco
    • Joe Craft
    News & Views
  • Determining the immune crosstalk between macrophages and NK cells in bronchioalveolar lavage fluid during SARS-CoV-2 infection in macaques identifies immunoregulatory properties of NK cells and their implications for viral persistence.

    • Kewreshini Naidoo
    • Marcus Altfeld
    News & Views
Top of page ⤴

Research Briefings

  • Cancer cells often overexpress CD47, which triggers the macrophage receptor SIRPα to elude anti-tumor immunity. We found that CD47 also suppresses phagocytosis by masking a pro-phagocytic ligand, SLAMF7, on tumor cells. We generated a first-in-class SLAMF7 antibody, which dissociated the CD47–SLAMF7 cis interaction, enabling anti-tumor immunity during SIRPα blockade.

    Research Briefing
  • Interleukin-27 (IL-27) is a pleiotropic cytokine known for its diverse immune regulatory properties. Although innate immune cells are considered the major cellular sources of IL-27, we found that gut regulatory T cells (Treg cells) secrete IL-27 under inflammatory conditions, allowing them to selectively limit intestinal helper T17 cell (TH17 cell) responses in various disease settings.

    Research Briefing
Top of page ⤴

Review Articles

Top of page ⤴

Articles

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links